BioSpace News Archive

The Insight Partners published latest research study on “Human Microbiome Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product (Probiotics, Foods, Prebiotics, Medical Foods, Diagnostic Device, Drugs and Supplements)

The Insight Partners published latest research study on “Influenza Vaccines Market Size, Share, Revenue, Growth Strategy, Industry Trends and Forecast to 2028

Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, today announced that it has appointed Rita Laeufle, MD, PhD, as Chief Medical Officer, effective June 1, 2023.

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, today announced that it has completed enrollment of the pivotal Phase III clinical study for Hyalofast (Hyalofast 15-01) on its path to achieving FDA approval in the United States.

Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, announced that members of the management team will participate in the upcoming 20th Annual Craig-Hallum Institutional Investor Conference on May 31st, 2023.

Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced presentations and posters to be shared at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting demonstrating the utility of adagrasib across multiple tumor types.

Azenta, Inc. announced that Company management will participate in the Jefferies Healthcare Conference in New York, NY, on Thursday, June 8, 2023, which includes a presentation beginning at 11:30 am ET.

Arcus Biosciences (NYSE:RCUS) announced that its management team will participate in a fireside chat at the upcoming Goldman Sachs 44th Annual Global Healthcare Conference at the Waldorf Astoria Monarch Beach Resort & Club in Dana Point, California.

Seres Therapeutics, Inc. announced that the Company has received a $125 million milestone payment from Nestlé Health Science related to the U.S. Food and Drug Administration approval of VOWST™, an orally administered microbiota-based therapeutic to prevent recurrence of C. difficile Infection in adults following antibiotic treatment for recurrent CDI.

AnaptysBio, Inc. announced that Daniel Faga, interim president and chief executive officer of AnaptysBio, and other members of its senior management team are scheduled to participate in both of the upcoming investor conferences below: